Photo from Ben Derman/Twitter
Aug 16, 2023, 19:07
Ben Derman: Some thoughts on Elrantamab in light of approval.
Dr. Ben Derman, Assistant Professor at the University of Chicago, recently shared in a Twitter post:
“Some thoughts on Elrantamab in light of approval:
– Similar Overall Response Rate (ORR) to tec, but we have no data on Progression-Free Survival (PFS) or Duration of Response (DoR). I have yet to see a publication of MagnetisMM-3.
– Package insert: hospitalization recommends for the first 2 step-up doses but not the 3rd.
– q2wk for responders after cycle 6.”
Source: Ben Derman/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46